Top Cancer Researcher Fails to Disclose Corporate Financial Ties in Major Research Journals

By | September 10, 2018

Board of Directors

■ Aura Biosciences* (cancer startup)

■ Bristol-Myers Squibb

■ Foghorn Therapeutics (cancer startup)

■ Grail* (cancer testing startup)

■ Infinity Pharmaceuticals* (cancer startup)

■ Varian Medical Systems (radiation equipment)

Scientific or Clinical Advisory Board

■ ApoGen Biotechnologies (cancer startup)

■ Aura Biosciences (cancer startup)

■ Grail (cancer testing startup)

■ Juno Therapeutics*

■ Northern Biologics (cancer startup)

■ Paige.AI (pathology startup)

■ Peptomyc* (cancer startup)

■ PMV Pharmaceuticals (cancer startup)

■ Seragon Pharmaceuticals* (breast cancer)

Founder or Co-Founder

■ Mosaic Biomedicals*

■ Tango Therapeutics (cancer startup)

Paid Consultant

■ AstraZeneca*

■ Eli Lilly*

■ Novartis*

■ Roche/Genentech*

NYT > Health

See also  Antibiotic resistance on rise: UK doctors